Abstract:Recent longitudinal PET imaging studies have established methods to estimate the age at which amyloid becomes abnormal at the level of the individual. Here we recontextualized amyloid levels into the temporal domain to better understand the downstream Alzheimer's disease processes of tau neurofibrillary tangle (NFT) accumulation and cognitive decline. This cohort study included a total of 601 individuals from the Wisconsin Registry for Alzheimer's Prevention and Wisconsin Alzheimer's Disease Research Center that underwent amyloid and tau PET, longitudinal neuropsychological assessments, and met clinical criteria for three clinical diagnosis groups: cognitively unimpaired (CU; n =537); mild cognitive impairment (MCI; n =48); or dementia ( n =16)). Cortical 11 C-Pittsburgh compound B (PiB) distribution volume ratio (DVR) and sampled iterative local approximation were used to estimate amyloid positive (A+; global PiB DVR>1.16 equivalent to 17.1 Centiloids) onset age and years of A+ duration at tau PET (i.e., amyloid chronicity). Tau PET burden was quantified using 18 F-MK-6240 standardized uptake value ratios (SUVRs; 70-90 min, inferior cerebellar gray matter reference region). Whole-brain and region-specific approaches were used to examine tau PET binding along the amyloid timeline and across the Alzheimer's disease clinical continuum. Voxel-wise 18 F-MK-6240 analyses revealed that with each decade of A+, the spatial extent of measurable tau spread (i.e., progressed) from regions associated with early to late NFT tau stages. Regional analyses indicated that tau burden in the entorhinal cortex was detectable, on average, within ten years of A+ onset. Additionally, the entorhinal cortex was the region most sensitive to early amyloid pathology and clinical impairment in this predominantly preclinical sample. Among initially CU ( n =472) individuals with longitudinal cognitive follow-up, mixed effects models showed significant linear and non-linear interactions of A+ duration and entorhinal tau on cognitive decline, suggesting a synergistic effect whereby greater A+ duration together with a higher entorhinal tau burden increases the likelihood of cognitive decline beyond their separable effects. Overall, the amyloid time framework enabled a spatiotemporal characterization of tau deposition patterns across the Alzheimer's disease continuum. This approach, which examined cross-sectional tau PET data along the amyloid timeline to make longitudinal disease-course inferences, demonstrated that A+ duration explains a considerable amount of variability in the magnitude and topography of tau spread, which largely recapitulated NFT staging observed in human neuropathological studies. By anchoring disease progression to the onset of amyloid, this study provides a temporal disease context which may help inform disease prognosis and timing windows for anti-amyloid therapies.

Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum

Disentangling the heterogeneity of brain atrophy in Alzheimer’s Disease

Elucidating the neuropathological and molecular heterogeneity of amyloid-beta and tau in Alzheimer's disease through machine learning and transcriptomic integration

Structural Brain Differences in the Alzheimer's Disease Continuum: Insights Into the Heterogeneity From a Large Multisite Neuroimaging Consortium

Tau-PET abnormality change along with Alzheimer’s disease: a topological perspective

Oligomeric, phosphorylated, and truncated tau and spliceosome pathology within the entorhinal-hippocampal connectome across stages of Alzheimer's disease

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease

Topology-based Clustering of Functional Brain Networks in an Alzheimer's Disease Cohort

Local molecular and connectomic contributions of tau-related neurodegeneration

Disentangling brain heterogeneity via semi‐supervised deep‐learning and MRI: Application to dimensional representations of Alzheimer’s disease

Single-cell multiregion dissection of Alzheimer's disease

Investigating the Effect of Tau Deposition and Apoe on Hippocampal Morphometry in Alzheimer's Disease: A Federated Chow Test Model.

Disentangling Alzheimer's disease neurodegeneration from typical brain aging using machine learning

Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease

Uncovering the System Vulnerability and Criticality of Human Brain under Dynamical Neuropathological Events in Alzheimer's Disease

Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning: Introducing THETA, a Novel Tau Summary Measure

The Heterogeneity of Asymmetric Tau Distribution is Associated with an Early Age at Onset and Poor Prognosis in Alzheimer’s Disease

Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease

Characterization of tau propagation pattern and cascading hypometabolism from functional connectivity in Alzheimer's disease

Heterogeneity of tau deposition and microvascular involvement in MCI and AD